Stock

Endeavour Completes US$100 Million Investment By La Mancha

Friday, July 3, 2020 - 3:56pm

This forward-looking information may be affected by risks and uncertainties in the combined business of Endeavour and market conditions.

Key Points: 
  • This forward-looking information may be affected by risks and uncertainties in the combined business of Endeavour and market conditions.
  • r.l., indirectly through La Mancha Africa Holding Limited, owns 39,329,731 ordinary shares of Endeavour, representing approximately 24.1% of the issued and outstanding shares of Endeavour.
  • The La Mancha investment in Endeavour is being undertaken for investment purposes and La Mancha may, from time to time, acquire additional securities of Endeavour or dispose of all or a portion of the ordinary shares of Endeavour previously acquired or held.
  • Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

ATTENTION EXERCISE AND HOLD STRATEGY INVESTORS WITH EMPLOYER COMPANY STOCK: KlaymanToskes Commences Investigation into Full-service Brokerage Firms for Mismanagement of Concentrated, Leveraged Positions in Employer Company Stock

Thursday, July 2, 2020 - 10:20pm

NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- National investment fraud law firm, KlaymanToskes (KT), commences an investigation into full-service brokerage firms for the mismanagement of concentrated, company stock positions accumulated through employer sponsored plans.

Key Points: 
  • NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- National investment fraud law firm, KlaymanToskes (KT), commences an investigation into full-service brokerage firms for the mismanagement of concentrated, company stock positions accumulated through employer sponsored plans.
  • The investigation focuses on whether full-service brokerage firm recommendations for an exercise and hold strategy represents unsuitable investment advice and a failure to supervise the management of concentrated, leveraged positions in employer company stock.
  • Investment portfolios holding large concentrated stock positions carry significant downside risks, especially when leveraged by a margin loan.
  • The sole purpose of this release is to investigate whether strategies deployed by full-service brokerage firms were suitable for investors with concentrated, leveraged stock positions in employer company stock.

Aditx Therapeutics, Inc. (Aditxt) Announces Closing of Initial Public Offering

Thursday, July 2, 2020 - 9:10pm

The underwriters continue to hold a 45-day option to purchase up to an additional 184,000 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

Key Points: 
  • The underwriters continue to hold a 45-day option to purchase up to an additional 184,000 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.
  • The common stock and the accompanying warrants included in the units were purchased together in this offering but were issued separately and were immediately separable upon issuance.
  • The Companys common stock began trading on the Nasdaq Capital Market under the ticker symbol ADTX on June 30, 2020.
  • Sheppard, Mullin, Richter, & Hampton LLP served as counsel to the Company in this offering.

Liquidia Announces Closing of Public Offering of Common Stock

Thursday, July 2, 2020 - 9:01pm

RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINTtechnology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINTtechnology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia.
  • All of the shares in the offering were sold by Liquidia.
  • In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less the underwriting discount and commissions.
  • The proposed offering was made only by means of a written prospectus and prospectus supplement that form part of the registration statement.

RTI Surgical Holdings, Inc.® to Hold Virtual-Only Annual Meeting of Stockholders

Thursday, July 2, 2020 - 9:05pm

To take part in the Annual Meeting, stockholders can join the webcast at www.virtualshareholdermeeting.com/RTIX2020 (the Annual Meeting Website).

Key Points: 
  • To take part in the Annual Meeting, stockholders can join the webcast at www.virtualshareholdermeeting.com/RTIX2020 (the Annual Meeting Website).
  • To be admitted to the webcast on the Annual Meeting Website, stockholders must enter the control number found on the stockholders proxy card, voting instruction form, or notice previously received by stockholders.
  • Stockholders may vote during the Annual Meeting by following the instructions available on the Annual Meeting Website.
  • Stockholders will also have the opportunity to submit questions during the virtual event by using the directions available on the live Annual Meeting Website.

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)

Thursday, July 2, 2020 - 9:30pm

Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Synchronoss granted the one newly hired employee an aggregate of 675 time-based restricted stock awards.
  • In addition, the employees received an aggregate of 225 time-based stock option awards.
  • Synchronoss secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their business.

Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

Thursday, July 2, 2020 - 10:00pm

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of 2,000,000 shares of its common stock have exercised in full their option to purchase an additional 300,000 shares of common stock at the public offering price of $37.00 per share, less underwriting discounts and commissions.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of 2,000,000 shares of its common stock have exercised in full their option to purchase an additional 300,000 shares of common stock at the public offering price of $37.00 per share, less underwriting discounts and commissions.
  • The gross proceeds to Castle Biosciences from the offering, including the shares sold pursuant to the underwriters option, before deducting the underwriting discounts and commissions and offering expenses, were $85.1 million.
  • SVB Leerink and Baird were joint book-running managers for the offering and representatives of the underwriters.
  • Incorporated, Attention: Syndicate Department, 777 East Wisconsin Ave., Milwaukee, WI 53202, by telephone: (800) 792-2473, or by email: syndicate@rwbaird.com .

Green Star Products To Hold Stockholders Meeting

Thursday, July 2, 2020 - 3:30pm

SALT LAKE CITY, UT, July 02, 2020 (GLOBE NEWSWIRE) -- Today July 2nd, 2020, the President of Green Star Products, Inc. (PINKSHEETS: GSPI), Joseph LaStella, announced that the Company will be holding a Stockholders Meeting this fall as soon as its safe for a formal gathering of shareholders.

Key Points: 
  • SALT LAKE CITY, UT, July 02, 2020 (GLOBE NEWSWIRE) -- Today July 2nd, 2020, the President of Green Star Products, Inc. (PINKSHEETS: GSPI), Joseph LaStella, announced that the Company will be holding a Stockholders Meeting this fall as soon as its safe for a formal gathering of shareholders.
  • Mr. LaStella also stated that the Company is working on its financial statements, and could have them completed in time for the Shareholders Meeting.
  • Green Star Products, Inc. (PINKSHEETS: GSPI) is an environmentally friendly Public Company dedicated to creating innovative and cost effective products to improve the quality of life and the environment.
  • Forward-looking statements in the release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.

Polar Power Announces $2.8 Million Private Placement

Thursday, July 2, 2020 - 2:25pm

GARDENA, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Polar Power, Inc. (NASDAQ: POLA), a global provider of prime, backup and solar hybrid power solutions, today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately $2.8 million through the private placement of its equity securities.

Key Points: 
  • GARDENA, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Polar Power, Inc. (NASDAQ: POLA), a global provider of prime, backup and solar hybrid power solutions, today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately $2.8 million through the private placement of its equity securities.
  • Polar Power will sell an aggregate of 1,250,000 shares of the Companys common stock at $2.25 per share.
  • Polar Power intends to use the net proceeds from the offering for working capital purposes.
  • Polar Power has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement.

Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

Thursday, July 2, 2020 - 2:00pm

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (Neoleukin) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to designde novoprotein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share.

Key Points: 
  • SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (Neoleukin) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to designde novoprotein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share.
  • The aggregate gross proceeds from this offering are expected to be approximately $76.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin.
  • Neoleukin has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock in connection with the public offering.
  • Examples of forward-looking statements include, among others, statements Neoleukin makes regarding its ability to complete the offering and expected use of proceeds.